Reframing Rescue Therapy to Help Prevent Asthma Exacerbations

06:30 PM - 09:30 PM

Please join us as we discuss asthma burden in the United States. Attendees will gain an increased understanding of the role of variable airway inflammation in the occurrence of severe exacerbations and consequent burden of systemic corticosteroid exposures for patients with asthma; how composite control tools such as the Asthma Impairment and Risk Questionnaire (AIRQ®) can better assess asthma control and help predict future exacerbations; patient preferences for immediate symptom relief; and recent recommendations from GINA and NAEPP. Data on a new rescue therapy treatment option will be reviewed.

Speakers: Demondes Haynes MD The University of Mississippi Medical Center; Maureen George RN, PhD Columbia University School of Nursing; Reynold Panettieri, Jr. MD Rutgers Institute for Translational Medicine and Science/Rutgers University; Bradley Chipps MD Capital Allergy and Respiratory Disease Center

Company: AstraZeneca

ILD in Surround Sound: The Pulm/Rheum Perspective

06:30 PM - 09:30 PM

At this non-CME educational event, pulmonologist Raj Dasgupta, MD and rheumatologist Rohit Aggarwal, MD will shed light on the process of diagnosing autoimmune-associated interstitial lung disease. Through their dual perspectives from both pulmonology and rheumatology fields, they will provide invaluable insights into not just diagnosing but also managing patients with this disease. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers: Rohit Aggarwal MD, MS University of Pittsburgh; Raj Dasgupta MD, FACP, FCCP, FAASM University of Southern California

Company: Boehringer Ingelheim Pharmaceuticals, Inc.

Guideline-Driven Care to Reduce Exacerbations in Moderate-to-Severe Asthma

06:30 PM - 09:30 PM

This will enhance clinicians’ ability translate evidence-based guidelines into clinical strategies to inform prompt diagnosis, treatment selection/adjustments and reduce the occurrence of exacerbations; improve the implementation of individualized treatment plans that include patient communication, education, and shared decision making; and to design treatment regimens that incorporate guideline recommendations and the latest in clinical trial data for approved therapeutic agents.

Speakers: Njira Lugogo MD University of Michigan, Ann Arbor, MI; Diego J. Maselli MD UT Health at San Antonio, San Antonio, TX

Company: Regeneron Pharmaceuticals, Inc. and Sanofi

A Discussion Amongst Experts: Addressing the Complexities of Titrating PAH Therapy (Open to U.S. attendees only)

06:30 PM - 09:30 PM

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by restricted blood flow through the pulmonary vasculature ultimately leading to right heart failure. The management of PAH is complex and requires comprehensive, multidisciplinary care. This symposium will feature an expert panel who will discuss clinical strategies for titrating PAH therapy and empowering patients across the disease trajectory.

This promotional educational activity is brought to you by Janssen and is not certified for CME. The consultant is a paid speaker for Janssen. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.

Speakers: Sean Studer MD The Janssen Pharmaceutical Companies of Johnson & Johnson; Richard Channick MD David Geffen School of Medicine at UCLA; J. Wesley McConnell MD Norton Healthcare; Sandra Lombardi RN UCSD

Company: Janssen

PH-ILD Reimagined: 2023 Updates in Disease State, Treatment, and Device Options

06:30 PM - 09:30 PM

Pulmonary hypertension (PH), a common complication of interstitial lung disease (ILD), is associated with poor outcomes. With therapeutic advancements in the field, there is now an FDA-approved treatment with multiple administration options for patients with PH-ILD.  

We have gathered experienced clinicians in the field, including Dr. Cedric J. Rutland (West Coast Lung), Dr. Steven Nathan (Inova Fairfax), and Dr. Colleen McEvoy (Washington University School of Medicine). This event aims to provide a comprehensive overview of the disease state, treatment approach, and characteristics of DPI devices. We welcome you to join us for this exciting opportunity.

Speakers: Cedric J. Rutland MD West Coast Lung; Steven Nathan MD Inova Fairfax Hospital; Colleen McEvoy MD Washington University School of Medicine

Company: United Therapeutics Corporation

Understanding Chronic Cough: Patient Presentation and Assessment (Open to U.S. attendees only)

06:30 PM - 09:30 PM

Learning Objectives:

• Discuss patient cases and understand patient presentation of chronic cough
• Review clinical guidelines
• Understand potential mechanisms of disease in chronic cough

Speaker: Dr. Reynold Panettieri Jr. M.D. Robert Wood Johnson Medical School and Rutgers Biomedical and Health Sciences

Company: Merck & Co., Inc.

Nontuberculous Mycobacterial Lung Disease (NTM-LD): Overcoming Common Pitfalls in Diagnosis and Treatment

06:30 PM - 09:30 PM

This presentation will help HCPs reduce time to diagnosis in patients with suspected NTM-LD; individualize treatment selection for patients with NTM-LD in frontline and refractory settings based on clinical guidelines and patient characteristics; evaluate the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD; and optimize strategies to avoid and manage the adverse effects of antibiotic therapy in patients with NTM-LD and facilitate the completion of therapy.

Speakers: Charles Daley MD National Jewish Health, Denver, CO; Shannon Kasperbauer MD National Jewish Health, Denver, CO

Company: Insmed

Answering the Call in Severe Asthma: Expanding Roles for Biologic Treatment Regimens

06:30 PM - 09:30 PM

This live Call-a-Colleague™ educational program will guide attendees through the long-term management of severe asthma. Expert faculty will provide actionable recommendations on evaluation strategies that consider underlying mechanism of disease, data on newer biologic treatment options, and most importantly, the use of these therapies in current day practice. Interspersed throughout the program are brief video calls in which faculty consult with their specialist colleagues to inform management decisions and gain additional insights into health disparities in asthma care and access, comorbid disease, initiation of biologics early within the disease course, and finally, treatment selection for challenging clinical cases.

Speakers: Monica Kraft MD Icahn School of Medicine at Mount Sinai; Mount Sinai Health System; Reynold A. Panettieri, Jr MD Child Health Institute of New Jersey; Rutgers, The State University of New Jersey; Jonathan Corren MD David Geffen School of Medicine; University of California, Los Angeles; Njira Lucia Lugogo MD, MS Division of Pulmonary & Critical Care Medicine; University of Michigan Pulmonary & Critical Care Medicine

Company: AstraZeneca

Disrupting the Vicious Vortex in NCFBE: The Evolving Role of Emerging Neutrophil Agents

06:30 PM - 09:00 PM

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic debilitating pulmonary disease involving a vicious cycle of infection, inflammation, and damaged airways. Join us for this hybrid CME event where Drs. Metersky, Aksamit, and Johnson will help you improve your NCFBE diagnostic and therapeutic skills. Learn about novel emerging treatment strategies for NCFBE, including targeting the activation of neutrophil serine proteases and neutrophilic inflammation. An experienced patient with NCFBE will share a very personal journey and provide impactful messages for healthcare professionals. To participate in the virtual stream, visit https://RMEI.com/NCFBE523.

Speakers: Mark Metersky MD UConn Health, Farmington, CT; Timothy R. Aksamit MD Mayo Clinic, Rochester, MN; Margaret M. Johnson MD Mayo Clinic, Jacksonville, FL

Company: RMEI Medical Education, LLC

Raising the Standard in Pulmonary Arterial Hypertension: Contemporary Approaches to Risk-Guided Treatment (Open to U.S. attendees only)

06:30 PM - 09:00 PM

Speakers: TBA ; TBA ; TBA ; TBA ; TBA

Company: Medscape